Presentation and Management of Psychosis in Parkinson’s Disease and Dementia With Lewy Bodies
- 1 October 2007
- journal article
- case report
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 164 (10), 1491-1498
- https://doi.org/10.1176/appi.ajp.2007.07040715
Abstract
A 73-year-old man with a 10-year history of progressive Parkinson’s disease is referred for psychiatric evaluation and treatment by a neurologist for new-onset confusion and visual hallucinations of strangers in his house. Treatment of the early Parkinson’s symptoms began with a dopamine agonist, and /-dopa was added later to combat worsening tremor, rigidity, slowed mobility, and difficulty performing basic activities of daily living. A more detailed history elicits new-onset depression and vivid dreaming with insomnia. The patient’s wife is concerned about the hallucinations, worsening cognitive impairment, and disturbed sleep, all of which have an impact on her quality of life. Treatment options for addressing these new symptoms include lowering the dosages of antiparkinsonian medications, which can cause or aggravate visual hallucinations and confusion, or adding quetiapine, the atypical antipsychotic drug that is least likely to worsen the parkinsonism. After discussions with the patient and his wife, the decision is made to initiate quetiapine at a dose of 50 mg at bedtime and not to change the antiparkinsonian medication regimen. However, after only a few doses, the patient stops taking the quetiapine because of excessive sedation and increased confusion. An attempt is then made to slowly taper the dopamine agonist, which is more likely than /-dopa to cause psychiatric complications and is less effective as an antiparkinsonian medication. The patient’s parkinsonism worsens, however, so the dosage is restored to the previously effective level. The patient’s condition continues to deteriorate because of increasing visual hallucinations (now accompanied by persecutory delusions regarding the strangers in the house), confusion, and disturbed sleep. An urgent follow-up evaluation is arranged.Keywords
This publication has 54 references indexed in Scilit:
- Treating dopamimetic psychosis in Parkinson's disease: Structured review and meta-analysisEuropean Neuropsychopharmacology, 2007
- Frequency and correlates of co-morbid psychosis and depression in Parkinson's diseaseParkinsonism & Related Disorders, 2006
- Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's diseaseMovement Disorders, 2006
- Pharmacologic Interventions for Psychosis and Agitation in Neurodegenerative Diseases: Evidence About Efficacy and SafetyPsychiatric Clinics of North America, 2005
- Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover studyJournal of Neurology, Neurosurgery & Psychiatry, 2005
- Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow upJournal of Neurology, Neurosurgery & Psychiatry, 2004
- Randomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson's diseaseInternational Journal of Geriatric Psychiatry, 2004
- Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobeBrain, 2002
- Risk factors for dementia, depression and psychosis in long-standing Parkinson's diseaseJournal of Neural Transmission, 2000
- The Neuropsychiatric InventoryNeurology, 1994